Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Rituximab Maintenance in Relapsed/Refractory Mantle-cell Lymphoma
NCT02267915Phase 2Unknown
- Sponsor
- GELTAMO
- Start
- Mar 2015
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in mantle cell lymphoma (MCL), sponsored by GELTAMO. Status: unknown.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02267915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267915.